Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


February 28, 2013
HIV Accelerates Liver Fibrosis by Nearly a Decade Among People With Hep C
Fibrosis in those coinfected with hepatitis C and HIV is comparable in severity to that found in people mono- infected with hep C who are nearly a decade older.
February 27, 2013
'Intensified' Antiretroviral Regimen Reduces Viral Shedding in Semen
The addition of Selzentry and Isentress to a standard HIV regimen rapidly and significantly reduces the likelihood of low level shedding of the virus in semen.
The Brain as the Ideal Reservoir for HIV, Foiling Eradication Attempts
The brain is a reservoir for HIV, where the virus develops brain-specific mutations that may make it more virulent against the central nervous system. 
February 23, 2013
25% of U.S. Heterosexual Encounters Involve a Condom
A recent survey of sexual behavior in the United States has found that one in four heterosexual adults used a condom for their last vaginal intercourse.
February 22, 2013
Seattle Campaign to Alert Gay Men to Acute HIV Symptoms Largely Falls Flat
A campaign to educate Seattle gay men about acute HIV infection has had no influence testing behavior and a limited impact on knowledge.
February 20, 2013
New Evidence Suggests Hepatitis C Transmits Sexually Among HIV-Positive Gay Men
Sexual transmission and non-injection drug use may be to blame for high levels of hepatitis C infection among HIV-positive gay men at a Boston clinic.
Uganda Study Adds to Growing Proof of Treatment as Prevention’s Success
A study of serodiscordant heterosexual couples in Uganda has found that no HIV-positive partner transmitted HIV while taking antiretrovirals.
February 19, 2013
FDA Grants Priority Review Designation for ViiV’s Dolutegravir
The FDA has granted ViiV Healthcare priority review designation for the company’s new integrase inhibitor dolutegravir, treament-naive, salvage.
Sexually Transmitted Infections Cost the U.S. $16 Billion Per Year
The CDC estimates that there are 20 million new sexually transmitted infections in the US each year, with a price tag of $16 billion.
February 14, 2013
Widespread Testing Fails to Reduce HIV Incidence in English and Welsh Gay Men
The number of new infections among English and Welsh gay men population remained unchanged between 2001 and 2010 despite increased testing.
February 13, 2013
Tenofovir May Raise Risk of Kidney Damage, but Effect Tapers Over Time
Tenofovir raises the risk of kidney dysfunction among people with HIV, but the adverse effect occurs mostly within the first two years of therapy.  
FDA Approves Changes to Reyataz Label
Changes to the Reyataz label include new warnings about kidney and gall stones, interstitial nephritis, as well as updated drug interaction information.
February 08, 2013
Only One in Five Medicaid Recipients With HIV Are Linked to Care Within a Year of Diagnosis
Only one in five Americans on Medicaid who receive an HIV diagnosis are linked into HIV care within a year.
February 07, 2013
Minorities With HIV Fare Better With Culturally Competent Doctors
The health outcomes of minorities receiving HIV care is generally dependent on the cultural competency of their physicians.
Even With a Suppressed Viral Load, Mothers With HIV Should Not Breast-feed
The American Academy of Pediatrics says HIV-positive mothers should avoid breast-feeding, regardless of their viral load or whether they are on antiretrovirals.
February 06, 2013
People With HIV Have a Doubled Risk of Non-Melanoma Skin Cancers
The incidence of two non-melanoma skin cancers is more than twice as high among people with HIV as compared with the general population.
February 04, 2013
Mortality Rates Among People With HIV, Long on the Wane, Continue to Drop
Even nearly two decades into the modern antiretroviral era, the risk of death continues to drop for people living with HIV.
FDA Releases Updated Drug Interaction Information for Kaletra
The FDA has approved revisions to the label of the antiretroviral Kaletra (lopinavir/ritonavir) in order to include new information on drug interactions.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    oceanblue65
    louisiana
    Louisiana


    latinpozdallas
    Dallas
    Texas


    thebake
    Sioux Falls
    South Dakota
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.